Summary & Overview
HCPCS J2860: Injection, siltuximab, 10 mg
HCPCS Level II code J2860 denotes injection of siltuximab, billed per 10 mg unit. Siltuximab is a monoclonal antibody used in specialty oncology and inflammatory conditions, and precise coding ensures appropriate coverage and claims processing for high-cost infused biologics. Nationally, accurate reporting of drug units supports reimbursement consistency, utilization tracking, and pharmacy benefit coordination for infused therapies.
This analysis covers major national payers: Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of payer coverage themes, coding and billing benchmarks, and clinical context relevant to infusion of specialty biologics. The publication summarizes typical site-of-service considerations and common billing practices for high-cost injectable agents.
What readers will learn: standardized description of J2860, expected service settings, key payer coverage categories, common billing modifiers and practice patterns (listed elsewhere in the publication), and gaps where input data was not provided. Data not available in the input is noted in the detailed sections.
Billing Code Overview
HCPCS Level II code J2860 represents the drug siltuximab, billed per 10 mg unit for injection. This code is used for administration of the medication in clinical settings where intravenous biologic oncology or specialty immunotherapy drugs are delivered.
Service type: Injection (intravenous biologic/specialty oncology agent)
Typical site of service: Outpatient infusion center or hospital outpatient department
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A 62-year-old male with multicentric Castleman disease presents to the outpatient infusion center for scheduled intravenous therapy with siltuximab. The oncology advanced practice provider confirms weight and recent laboratory results, reviews prior infusion reactions, and obtains verbal consent. The pharmacy compounds J2860 per dose (10 mg per billing unit) and the infusion nurse performs baseline vital signs, places an IV catheter, and administers siltuximab over the recommended infusion time while monitoring for infusion-related reactions. Post-infusion observation includes vital signs at regular intervals and documentation of any adverse events. Subsequent visits follow a recurring dosing schedule with pre-visit labs and interval assessment of response and toxicity.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
11 | E/M services by the same physician or other qualified health care professional | Use when an evaluation and management service is separately reported on the same date as J2860 by the billing provider. |
22 |